Albumin Can Be Given in Critical Phase of Dengue
Yes, albumin can be administered during the critical phase of dengue, particularly in fluid-refractory shock, and recent evidence suggests it improves survival and reduces complications compared to crystalloids alone.
Evidence-Based Recommendation
The FDA-approved indications for albumin explicitly include hypovolemic shock and situations involving protein-rich fluid sequestration 1, which directly applies to dengue's pathophysiology of vascular leakage. While the 2024 international albumin guidelines 2 do not specifically address dengue (focusing on general critical care where albumin shows no mortality benefit over crystalloids), the dengue-specific research demonstrates a different risk-benefit profile.
When to Use Albumin in Dengue
Initiate albumin (0.5-1 g/kg of 25% solution) when:
- Patient remains in shock after 40 mL/kg of crystalloid/colloid boluses within 1-2 hours
- Signs of severe plasma leakage with ongoing hemodynamic instability
- Hypoalbuminemia with fluid overload
Supporting Evidence for Dengue-Specific Use
The most compelling recent data comes from a 2025 prospective study 3 showing that adding 25% albumin to standard treatment in fluid-refractory severe dengue resulted in:
- 97.1% survival vs. 77.1% with standard treatment alone (p=0.043)
- 60% requiring inotropes vs. 94.3% in standard treatment group (p<0.001)
- Significantly less bleeding, acute kidney injury, and need for renal replacement therapy
A 2024 multicenter randomized trial 4 demonstrated that early intervention with 5% albumin in DHF grades I-II showed:
- Better control of hemoconcentration at 4,12, and 24 hours
- Higher platelet counts and serum albumin levels
- Lower proteinuria
- Shorter hospital length of stay (p<0.001)
A 2018 pediatric study 5 using targeted ICU interventions including early albumin for crystalloid-refractory shock showed mortality reduction from 26% to 2.6% (p=0.004).
Critical Considerations and Pitfalls
Timing is crucial: Albumin should be given during the critical phase (typically days 3-7 of illness) when plasma leakage is maximal, not prophylactically in early dengue fever.
Monitor for circulatory overload: 25% albumin is hyperoncotic and expands plasma volume 3-4 times the infused volume 1. In dehydrated patients, additional crystalloids must be given concurrently, or 5% albumin should be used instead 1.
Avoid in certain situations: The FDA label 1 explicitly states albumin is not warranted in chronic nephrosis where it is promptly excreted, though this differs from acute dengue-related vascular leak.
Watch for rapid blood pressure rise: The oncotic effect may unmask previously non-bleeding vessels that were tamponaded at lower pressures 1.
Practical Algorithm
- Initial resuscitation: Start with crystalloids per WHO dengue guidelines
- Assess at 1-2 hours: If shock persists after 40 mL/kg crystalloid/colloid
- Add albumin: Give 0.5-1 g/kg of 25% albumin 3
- Monitor closely: Hematocrit, urine output, blood pressure, signs of fluid overload
- Prepare for deresuscitation: Once critical phase passes (typically 24-48 hours), transition to fluid removal with diuretics if needed
Reconciling Conflicting Evidence
The 2024 general critical care guidelines 2 show no mortality benefit for albumin in mixed ICU populations and even suggest harm in trauma (particularly traumatic brain injury). However, dengue represents a distinct pathophysiology—transient, reversible vascular leak without the same coagulopathy concerns as trauma. The dengue-specific studies 3, 4, 5 consistently show benefit, likely because albumin addresses the specific oncotic deficit and endothelial dysfunction characteristic of severe dengue 6.
The key distinction: General sepsis/shock guidelines don't apply directly to dengue's unique time-limited capillary leak syndrome. Hypoalbuminemia emerged as the strongest single biomarker for mortality prediction in dengue 7, supporting albumin's therapeutic role.